India Diabetes Drug Market Overview, 2030

India’s diabetes drug market is witnessing unprecedented growth, driven by a sharp rise in diabetes prevalence, changing lifestyles, expanding healthcare access, and regulatory support. As of Now, India is home to over 89.9 million people living with diabetes, and projections indicate this number will reach 156.7 million by 2050, making the country one of the largest diabetes populations globally. India has also witnessed a significant drop in diabetes drug prices due to a surge in domestic generics and biosimilars. Major Indian pharmaceutical companies like Sun Pharma, Dr. Reddy’s, and Biocon have launched affordable versions of expensive patented drugs. For example, empagliflozin, which previously cost ₹60 per tablet, is now available for under ₹10, thanks to the competition from Indian manufacturers. Moreover, Biocon’s entry into biosimilar GLP-1 and upcoming semaglutide versions reflect the nation’s role in advancing affordable innovation. In parallel, the government’s Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) initiative has played a pivotal role in distributing quality generic diabetes medicines at subsidized rates through over 10,000 Jan Aushadhi Kendras. In January 2024, Glenmark launched the first biosimilar of Liraglutide in India. Liraglutide is a popular drug used to treat type 2 diabetes mellitus in adults. The drug will be marketed under the brand name Lirafit for USD 1.20 and will be available only under prescription. The biosimilar launch will make the drug more accessible to patients in India as the cost will lower by up to 70%. For instance, according to a study conducted among patients with type 2 diabetes in India and published in November 2021, during the lockdown period, 30.6% of the patients who tried to consult a doctor utilized the telemedicine facility.

According to the research report, ""India Diabetes Drug Market Overview, 2030,"" published by Bonafide Research, the India Diabetes Drug market is anticipated to add to more than USD 970 Million by 2025–30. The primary driver of the India Diabetes Drugs market is the rapidly growing number of diabetes cases across the country. For instance, the International Diabetes Federation highlights that India accounts for nearly one in seven adults living with diabetes worldwide, emphasizing the scale of the issue. Additionally, urbanization and changes in dietary habits, including higher consumption of processed foods and reduced physical activity, have accelerated this trend. As the incidence of diabetes continues to rise, the demand for effective drug therapies to manage the condition also grows, propelling the market forward. In March 2023 Sanofi in India has recently obtained marketing authorization from the Central Drugs Standard Control Organization (CDSCO) for its diabetes medication, Soliqua™. This pre-filled pen drug is specifically designed to enhance glycemic control in adults with type 2 diabetes and obesity who have not achieved sufficient control through oral or injectable therapies. AstraZeneca India gets approval to market the anti-diabetes drug Dapagliflozin. The company said it had received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug indicated for diabetes patients with chronic kidney disease (CKD). Soliqua™ is administered once daily through pre-filled pens, containing a fixed-ratio combination of insulin glargine and lixisenatide in two different ratios (10-40 and 30-60). The rise of digital health technologies is shaping the future of diabetes management in India. Mobile health applications, continuous glucose monitors (CGMs), and telemedicine platforms are becoming increasingly popular among both patients and healthcare providers. For instance, the Digital India initiative has facilitated the development of telemedicine platforms that connect patients in rural areas with endocrinologists in urban centers, improving access to specialized care.

Insulin continues to be a vital therapeutic choice, especially for Type 1 diabetes and advanced stages of Type 2 diabetes. India is also one of the leading producers of insulin, and biosimilar insulin availability has improved access and affordability. However, adherence remains a challenge due to injection aversion and cost concerns in some population segments. GLP-1 receptor agonists, such as liraglutide and semaglutide, are gaining traction in urban areas, primarily because of their dual benefits glycemic control and weight loss. Although relatively expensive, these are increasingly prescribed to patients with obesity-related Type 2 diabetes and cardiovascular risks, common among India’s urban diabetic population. DPP-4 inhibitors, like sitagliptin and teneligliptin, are among the most widely prescribed oral antidiabetic drugs in India due to their efficacy, safety profile, and affordability. Teneligliptin, in particular, has seen rapid adoption in India after its launch at lower price points compared to other countries. Its popularity stems from a good balance of cost-effectiveness and therapeutic value, making it ideal for the middle-income group. SGLT2 inhibitors, including dapagliflozin and empagliflozin, are also gaining momentum, especially in patients with a high risk of cardiovascular or renal complications. India has seen a growing incidence of such comorbidities, making this class a popular second-line therapy. However, cost is still a limiting factor in its wider adoption across semi-urban and rural settings. The ""Others"" category, comprising metformin, sulfonylureas, and combination therapies, forms the backbone of initial diabetes treatment in India. Metformin remains the first-line therapy due to its low cost, high efficacy, and favorable safety profile. Sulfonylureas like glimepiride are still widely used in cost-sensitive demographics. Fixed-dose combinations (FDCs) of metformin with DPP-4 inhibitors or sulfonylureas are popular for their convenience and compliance, particularly among elderly patients.

Type 1 diabetes, although relatively rare compared to Type 2, affects approximately 10% of the diabetic population in India and primarily manifests in children and adolescents. It is characterized by the autoimmune destruction of pancreatic beta cells, leading to an absolute insulin deficiency. In India, the availability and affordability of insulin are key concerns for Type 1 patients, particularly in rural and low-income areas. The demand for more accessible biosimilar insulin products, insulin pens, and continuous glucose monitoring (CGM) systems is growing, as these can help improve treatment adherence and glycemic control. Type 2 diabetes constitutes nearly 90% of diabetes cases in India and is witnessing a sharp rise due to rapid urbanization, sedentary lifestyles, unhealthy diets, and genetic predisposition. India currently has over 100 million people living with diabetes, making it one of the countries with the highest diabetic populations globally. In Type 2 diabetes, the body becomes resistant to insulin or fails to produce enough insulin, leading to elevated blood glucose levels. This segment demonstrates a diverse demand for oral hypoglycemic agents and newer classes of drugs. Metformin remains the first-line therapy, while DPP-4 inhibitors (like Teneligliptin and Sitagliptin) have gained traction due to their affordability and safety profiles. Additionally, SGLT2 inhibitors and GLP-1 receptor agonists are becoming popular due to their cardiovascular and renal protective benefits, though their high cost limits widespread adoption. The Indian market is also witnessing a surge in fixed-dose combinations (FDCs) of metformin with other agents, catering to the convenience-driven demand from patients and doctors.

Common oral medications such as metformin, sulfonylureas, DPP-4 inhibitors, and SGLT2 inhibitors are widely prescribed, especially in outpatient settings and rural areas, where medical infrastructure for injectable therapies may be limited. According to the International Diabetes Federation (IDF), India had over 77 million diabetic individuals in 2024, many of whom prefer oral therapies for convenience and cost-effectiveness. The subcutaneous segment is growing steadily, driven by the rising prevalence of insulin-dependent diabetes and increasing awareness around insulin therapies and GLP-1 receptor agonists. Subcutaneous administration is essential for Type 1 diabetes and advanced Type 2 cases requiring insulin therapy. The increasing availability of insulin pens, prefilled syringes, and digital insulin delivery devices has significantly enhanced patient adherence in urban regions. Multinational pharmaceutical companies have been working with the Indian government to make insulin more affordable through initiatives like price caps and generic insulin formulations, contributing to the growth of this segment. The subcutaneous route also includes GLP-1 receptor agonists, which are gaining traction in India’s urban centers due to their added benefit of weight loss and cardiovascular protection, though their high cost remains a barrier for widespread use in low-income populations. The intravenous segment, while limited in comparison, is mostly confined to hospital settings, particularly for patients with diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), or those undergoing surgery or critical care requiring tight glucose control. Intravenous insulin and glucose solutions are part of emergency and inpatient care protocols but represent a small portion of overall diabetes drug consumption. The demand here is driven by tertiary care hospitals, increasing cases of acute complications, and the growing burden of diabetes-related hospitalizations.

Hospital pharmacies are crucial for patients undergoing inpatient care or receiving advanced diabetes management in tertiary care centers and specialty hospitals. These pharmacies primarily cater to patients with Type 1 diabetes, gestational diabetes, and those with multiple comorbidities requiring insulin therapy or combination regimens prescribed during hospitalization. They are known for offering a wide range of injectable and high-end insulin analogs, including basal-bolus insulin regimens and GLP-1 receptor agonists, which are typically initiated under medical supervision. Moreover, hospital pharmacies are often linked with public sector facilities, especially under government-run programs like Ayushman Bharat and Jan Aushadhi, making them vital for economically disadvantaged populations. Located ubiquitously in urban, semi-urban, and rural areas, these pharmacies are the primary source for oral antidiabetic drugs such as metformin, sulfonylureas, DPP-4 inhibitors, and fixed-dose combinations. Their accessibility and the ability to provide drugs without lengthy prescriptions make them the most preferred channel for Type 2 diabetes patients managing their condition through outpatient care. India’s growing geriatric population and rising middle-class income have further boosted demand at these outlets. Retail pharmacists also serve an informal consultative role, guiding patients on dosage, drug interactions, and diet adherence, especially in Tier II and III cities where access to endocrinologists is limited. Online pharmacies are rapidly transforming the diabetes drug landscape in India, driven by the growth of e-commerce, smartphone penetration, and digital health initiatives. Platforms like Netmeds, 1mg (now Tata 1mg), and PharmEasy are capitalizing on the demand for convenience, price discounts, doorstep delivery, and digital prescriptions. Online pharmacies are especially popular among tech-savvy younger populations and patients in metropolitan areas like Delhi, Mumbai, and Bengaluru.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Diabetic Drug Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Insulin
• GLP-1 Receptor Agonists
• DPP-4 Inhibitors
• SGLT2 Inhibitors
• Others (metformin, sulfonylureas, and combination therapies)

By Diabetes
• Type-1
• Type-2

By Route of Administration
• Oral
• Subcutaneous
• Intravenous

By Distribution Channel
• Hospital Pharmacies
• Retail pharmacies
• Online Pharmacies Show more